1. Is the Safety and Efficacy of Calcium Antagonists now Established?

   • Jørgen Fischer Hansen

   Legacy Pages: 145 - 147

2. Nifedipine After Acute Myocardial Infarction — Sola Dosis Facit Venenum*: Only the Dose Determines the Harm

   • Franz H. Messerli

   Legacy Pages: 149 - 150

3. The Inappropriate Use of Hypothesis Testing to Infer Safety of Calcium Channel Blockers

   • Frank E Harrell Jr.

   Legacy Pages: 151 - 153

4. Reply to Dr. Harrel’s Editorial Criticism

   • U. Goldbourt

   Letter Pages: 155 - 156

5. Calcium Channel Blockers and the Risk of Cancer: A Preclinical Assessment

   • Hans J. Ahr
   • Ernst Bomhard
   • Gerhard Schlüter

   OriginalPaper Pages: 157 - 169

6. Long-Term Mortality Follow-up of Hospital Survivors of a Myocardial Infarction Randomized to Nifedipine in the SPRINT Study

   • Henrietta Reicher-Reiss
   • Solomon Behar
   • Uri Goldbourt

   OriginalPaper Pages: 171 - 176

7. Nifedipine and Cancer Mortality: Ten-Year Follow-up of 2607 Patients After Acute Myocardial Infarction

   • Michael Jonas
   • Uri Goldbourt
   • Henrietta Reicher-Reiss

   OriginalPaper Pages: 177 - 181

8. Acute Myocardial Infarction Mortality Related to Use of Calcium Antagonists Before Admission to Hospital

   • K. Landmark
   • å Reikvam
   • I. Aursnes

   OriginalPaper Pages: 183 - 187

9. Adverse Reactions to Antihypertensive Therapy

   • Walter H. Aellig

   OriginalPaper Pages: 189 - 196

10. Selection of Drug Therapy in Stable Angina Pectoris

    • Stefano Savonitto
    • Diego Ardissino

    OriginalPaper Pages: 197 - 210

11. Safety, Tolerability, and Neurohormonal Changes of the Combination Captopril Plus Losartan in the Early Postinfarction Period: A Pilot Study

    • Pietro Di Pasquale
    • Vincenzo Bucca
    • Salvatore Paterna

    OriginalPaper Pages: 211 - 216

12. Increasing Nitroglycerin Release from Patches Enables Circumvention of Early Nitrate Tolerance

    • Günther Reiniger
    • Günter Lehmann

    OriginalPaper Pages: 217 - 224